Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › VENTURE (phase 2, s.c.)

VENTURE (phase 2, s.c.)

VK2735 · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
VK2735
Population
obesity
Phase
2
Participants
36
Duration
13 weeks

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
VK2735 5.0 mg weeklyobesity1335−10.9 % vs −1.7 %
Δ −9.2 pp
—−0.3 vs +0.011.0 vs 0.011.0 vs 14.046.0 vs 20.017.0 vs 0.06.0 vs 3.0−6.7 vs −4.2verified
VK2735 10 mg weeklyobesity1336−12.9 % vs −1.7 %
Δ −11.2 pp
—−0.3 vs +0.011.0 vs 0.014.0 vs 14.037.0 vs 20.017.0 vs 0.06.0 vs 3.0−7.0 vs −4.2verified
VK2735 15 mg weeklyobesity1335−14.7 % vs −1.7 %
Δ −13.0 pp
—−0.4 vs +0.020.0 vs 0.020.0 vs 14.063.0 vs 20.029.0 vs 0.03.0 vs 3.0−11.0 vs −4.2verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (24)
  • VK2735 5.0 mg weekly · weight_eff · Table 2
    LS Mean (95% CI) −1.7 (−3.03, −0.30) −9.1 (−10.43, −7.76) −10.9 (−12.25, −9.55) −12.9 (−14.30, −11.56) −14.7 (−16.11, −13.38)
  • VK2735 5.0 mg weekly · ae_dc · Table 3
    TEAE leading to treatment discontinuation 0 1 (3) 4 (11) 4 (11) 7 (20)
  • VK2735 5.0 mg weekly · disc_any · Table 3
    Discontinued treatment early, n (%)c 5 (14) 2 (6) 4 (11) 5 (14) 7 (20)
  • VK2735 5.0 mg weekly · nausea · Table 3
    Nausea 7 (20) 9 (26) 16 (46) 13 (37) 22 (63)
  • VK2735 5.0 mg weekly · vomiting · Table 3
    Vomiting 0 3 (9) 6 (17) 6 (17) 10 (29)
  • VK2735 5.0 mg weekly · sae · Table 3
    TESAEs, n (%)a 1 (3) 2 (6) 2 (6) 2 (6) 1 (3)
  • VK2735 5.0 mg weekly · hba1c · Table 5, Hemoglobin A1c
    Change from BL, LS Mean (SE) 0.03 (0.041) −0.29 (0.040) −0.27 (0.040) −0.27 (0.039) −0.36 (0.040)
  • VK2735 5.0 mg weekly · sbp · Table 5, Systolic blood pressure
    Change from BL, LS Mean (SE) −4.20 (1.993) −6.87 (1.906) −6.71 (1.931) −7.04 (1.936) −10.97 (2.000)
  • VK2735 10 mg weekly · weight_eff · Table 2
    LS Mean (95% CI) −1.7 (−3.03, −0.30) −9.1 (−10.43, −7.76) −10.9 (−12.25, −9.55) −12.9 (−14.30, −11.56) −14.7 (−16.11, −13.38)
  • VK2735 10 mg weekly · ae_dc · Table 3
    TEAE leading to treatment discontinuation 0 1 (3) 4 (11) 4 (11) 7 (20)
  • VK2735 10 mg weekly · disc_any · Table 3
    Discontinued treatment early, n (%)c 5 (14) 2 (6) 4 (11) 5 (14) 7 (20)
  • VK2735 10 mg weekly · nausea · Table 3
    Nausea 7 (20) 9 (26) 16 (46) 13 (37) 22 (63)
  • VK2735 10 mg weekly · vomiting · Table 3
    Vomiting 0 3 (9) 6 (17) 6 (17) 10 (29)
  • VK2735 10 mg weekly · sae · Table 3
    TESAEs, n (%)a 1 (3) 2 (6) 2 (6) 2 (6) 1 (3)
  • VK2735 10 mg weekly · hba1c · Table 5, Hemoglobin A1c
    Change from BL, LS Mean (SE) 0.03 (0.041) −0.29 (0.040) −0.27 (0.040) −0.27 (0.039) −0.36 (0.040)
  • VK2735 10 mg weekly · sbp · Table 5, Systolic blood pressure
    Change from BL, LS Mean (SE) −4.20 (1.993) −6.87 (1.906) −6.71 (1.931) −7.04 (1.936) −10.97 (2.000)
  • VK2735 15 mg weekly · weight_eff · Table 2
    LS Mean (95% CI) −1.7 (−3.03, −0.30) −9.1 (−10.43, −7.76) −10.9 (−12.25, −9.55) −12.9 (−14.30, −11.56) −14.7 (−16.11, −13.38)
  • VK2735 15 mg weekly · ae_dc · Table 3
    TEAE leading to treatment discontinuation 0 1 (3) 4 (11) 4 (11) 7 (20)
  • VK2735 15 mg weekly · disc_any · Table 3
    Discontinued treatment early, n (%)c 5 (14) 2 (6) 4 (11) 5 (14) 7 (20)
  • VK2735 15 mg weekly · nausea · Table 3
    Nausea 7 (20) 9 (26) 16 (46) 13 (37) 22 (63)
  • VK2735 15 mg weekly · vomiting · Table 3
    Vomiting 0 3 (9) 6 (17) 6 (17) 10 (29)
  • VK2735 15 mg weekly · sae · Table 3
    TESAEs, n (%)a 1 (3) 2 (6) 2 (6) 2 (6) 1 (3)
  • VK2735 15 mg weekly · hba1c · Table 5, Hemoglobin A1c
    Change from BL, LS Mean (SE) 0.03 (0.041) −0.29 (0.040) −0.27 (0.040) −0.27 (0.039) −0.36 (0.040)
  • VK2735 15 mg weekly · sbp · Table 5, Systolic blood pressure
    Change from BL, LS Mean (SE) −4.20 (1.993) −6.87 (1.906) −6.71 (1.931) −7.04 (1.936) −10.97 (2.000)

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: VENTURE (phase 2, s.c.). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/venture/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.